09:01 AM EDT, 05/06/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said Monday that the first patient has been dosed in a phase 2 trial of EDG-7500 in obstructive hypertrophic cardiomyopathy, or HCM.

EDG-7500 is an oral cardiac sarcomere modulator intended to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction, according to the company.

The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of EDG-7500 in patients with obstructive HCM, the company added.

Edgewise said it expects to report data from the single dose part of this trial and a phase 1 trial of EDG-7500 in healthy individuals in Q3.